embecta is a leading global diabetes care company, serving over 30 million individuals in more than 100 countries. With a 100-year legacy in insulin delivery, embecta continues to innovate in diabetes management, a disease affecting over 537 million people worldwide.
Innovation
An independent company after spinning off from Becton Dickinson in 2022, embecta embodies the spirit of a “100-yearold startup.” Leveraging its legacy of developing the first insulin syringe in 1924, the company drives innovation with cuttingedge products such as its proprietary disposable insulin delivery system, which recently received 510(k) clearance from the U.S. Food and Drug Administration. Indicated for adults who require insulin to manage diabetes, including both type 1 and type 2, the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers.
Talent Development
embecta is committed to Diversity, Equity, and Inclusion (DE&I) across its business. With a Board that is 67% ethnically and/or gender diverse and a senior leadership team that is 44% diverse, the company prioritizes DE&I in leadership and hiring. In 2023, they piloted a cross-cultural agility course and provided unconscious bias training to over 115 hiring managers in their manufacturing plants. This training equips managers with tools to make informed, unbiased hiring decisions.
Social Responsibility
embecta aligns its social responsibility with its values, partnering with 20+ diabetes-centered nonprofit organizations. They support programs like Beyond Type 1’s Diabetes Scholars, offering scholarships to students with type 1 diabetes, and the Diabetes Foundation’s education initiatives. The company’s Chief Medical Officer, Dr. Henry Anhalt, is a dedicated supporter of Camp Nejeda, a camp for children with type 1 diabetes, and embecta employees participate in volunteer activities at the camp throughout the year. Globally, embecta is committed to reducing waste through recycling, energy reduction, and alternative disposal methods. Their Suzhou, China site installed solar power, reducing carbon dioxide emissions by 771 tons annually. All embecta manufacturing sites carry ISO 14001 certification, ensuring active monitoring and reduction of environmental impacts.
FINALISTS:
Abbott
Boston Scientific
embecta
Fresenius
Regeneron
